Quantcast
Health

4 Commonly Prescribed Drugs That May Not Be Safe

They are so common no one thinks twice about them: drug ads that tell you about a disease you might have and a pill that could treat it. Just "ask your doctor," they say, if the pill is right for you.

Until 1997, such direct-to-consumer (DTC) ads did not exist because without a doctor’s recommendation, how could people know if the medication was appropriate or safe? The only thing people knew about drugs and drug risks was from ads they peeked at in medical journals at the doctor's office.

To sell drugs, the ads raise awareness of conditions people never worried about before and probably don't have.

But after the ads started in 1997, the allergy pill Claritin became a household word, along with Xenical, Meridia, Propecia, Paxil, Prozac, Vioxx, Viagra, Singulair, Nasonex, Allegra, Flonase and, of course, Lipitor—and Big Pharma became a Wall Street darling.

Now the American Medical Association (AMA) is taking a second look at DTC advertising. In November 2015, doctors at the AMA's Interim Meeting sought a policy to address one of its biggest problems: the growing proliferation of ads "driving demand for expensive treatments despite the clinical effectiveness of less costly alternatives." Billions are spent advertising expensive new drugs that are not clearly better than existing ones, the AMA said. The Kaiser Family Foundation agreed and said exorbitantly priced drugs—like $1,000-a-pill hepatitis C drugs and recently approved PCSK9-inhibiting cholesterol drugs—are the "public’s top health care priority." The new cholesterol drug will cost an estimated $14,000 a year.

Looting tax dollars and raising health premiums is only one result of DTC advertising. To sell drugs, the ads raise awareness of conditions people never worried about before and probably don't have. Some conditions are so rare the ads appear to be selling the disease itself. How many people, for example, suffer from "Non-24," a condition that mostly affects blind people yet is currently advertised on TV? How many people suffer from "exocrine pancreatic insufficiency" and need to ask their doctor about their "poop" as other ads currently suggest?

Nor are the drugs even clearly safe. Many of the aggressively advertised drugs have risks that have surfaced after their ad campaigns expire (Others like Vioxx, Bextra, Baycol, Trovan, Meridia, Seldane, Hismanal and Darvon were removed from the market altogether).

Here are some heavily advertised drugs that are not necessarily safe.

1. GERD Meds

Few had heard of the condition gastroesophageal reflux disease before DTC advertising. While a small percentage of the population may have GERD, the condition is widely believed to have been pushed to sell proton pump inhibitors (PPI) like Nexium. In many cases "GERD" is really heartburn and can be treated with Tums or Rolaids, critics said.

GERD has made a lot of money. The "Purple Pill," Nexium, made almost $5 billion in the U.S. in one year and the class of PPIs made $13.6 billion, translating into 119 million prescriptions. But safety questions have followed.

In 2012, the U.S. Food and Drug Administration (FDA) warned that PPIs are linked to Clostridium Difficile or C. Dif, a sometimes deadly intestinal infection that is becoming increasingly drug resistant. In 2013, medical literature linked PPIs to fractures, calcium and magnesium deficiencies, community-acquired pneumonia and vitamin B-12 deficiencies. Other research suggests PPIs might cause blood vessels to constrict and cardiovascular risks and this month, research said PPIs may be linked to increased risk for chronic kidney disease.

2. Lipitor

If DTC advertising was the medium that made Big Pharma a Wall Street darling, statins like Lipitor were the drug class. In 2005 statins earned $18.7 billion in the U.S. and Pfizer’s Lipitor became the best-selling drug in the world.

Patients loved statins because they could ignore diet and exercise advice and still, apparently, reduce heart attack risks; their body would "forgive" the bacon cheeseburger. But not all medical voices agreed. Some wondered why the nation spent approximately $20 billion a year on cholesterol-lowering drugs instead of effective, less dangerous and less expensive lifestyle and diet changes. Others questioned the value of statins themselves.

High cholesterol, which statins treat, is a "relatively weak risk factor for developing atherosclerosis," Barbara Roberts, an associate clinical professor of medicine at the Alpert Medical School of Brown University told me. "Big Pharma has consistently exaggerated the benefits of statins and some physicians used scare tactics so that patients are afraid that if they go off the statins, they will have a heart attack." Though many doctors have "swallowed the Kool-Aid," Dr. Roberts, author of The Truth about Statins, said, "diabetes and smoking are far more potent when it comes to increasing risk."

In 2012, the FDA floated new risks to the entire statin class, adding warnings to their labels about memory impairment, diabetes, liver injury and muscle damage. Memory problems had always been suspected with statins, but after Lipitor's patent ran out, they were confirmed.

3. Crestor

Statins were given a big boost by Paul Ridker of Brigham and Women's Hospital in Boston, who presented the results of a study on the statin Crestor, funded by its manufacturer AstraZeneca, in 2009. Even though Ridker was co-inventor of a related patent and stood to profit from sales and study authors listed 131 financial ties to Big Pharma, the media were wowed. Headlines screamed “AstraZeneca's Crestor cuts death, heart attack" and "Crestor study seen changing preventive treatment!" Ka-ching.

But doctors posting online comments in the New England Journal of Medicine were not convinced, especially since the study was stopped early because, AstraZeneca said, of its clearly positive results. "It is well established that RCTs [randomized controlled trials] stopped early overestimate benefits significantly," wrote a physician from Rochester, Minnesota. "It is shocking that this trial was terminated 50 percent through, based on a small absolute benefit, with real questions about long-term risk," a poster from LSU Law Center, read.

During Crestor-mania, few remembered that the FDA's own David Graham had named the drug among the top five most dangerous in Capitol Hill testimony. Public Citizen, the national watchdog group, had petitioned for the drug’s withdrawal and research in the journal Circulation found Crestor "was significantly more likely to be associated with the composite end point of rhabdomyolysis, proteinuria, nephropathy or renal failure" than related drugs.

4. Vytorin

Vytorin was heavily advertised as treating both genetic and dietary sources of cholesterol and combined the statin drug Zocor with the anti-hyperlipidemic drug Zetia. The problem was, it was marketed before a study confirmed its effectiveness and when the study was published, it found Vytorin had no effect on the buildup of plaque in the arteries. Oops.

Like other expensive and popular drugs, the issue wasn't just that Vytorin did not work any better than a much cheaper drug. Its makers, Merck and Schering-Plough, also admitted "theoretical" safety concerns about liver damage. In 2014, American Journal of Cardiology authors reported an unexpected increase in cancer incidence and mortality in subjects possibly linked to ezetimibe, one of the Vytorin ingredients.

Vytorin demonstrates well the AMA's current concerns about profiteering. The state of New York paid $21 million for Vytorin in two years out of its Medicaid dollars—a likely worthless drug. "Drug companies are on notice that concealing critical information about life-saving prescription drugs, profiting at the expense of patients' health and wasting taxpayer dollars, is simply unacceptable," then New York Attorney Andrew Cuomo, now governor, said.

Vytorin was such a scam, Sen. Chuck Grassley (R-Iowa) asked the General Accounting Office to investigate why the FDA would approve a drug to reduce artery-clogging plaque that didn't reduce artery-clogging plaque. Former Congressmen Bart Stupak (D-MI) and John Dingell (D-MI) asked why Schering-Plough Executive VP Carrie Smith Cox unloaded $28 million in stock when she knew the study failed before the public did.

"Many consumers may not have taken Vytorin had they been aware of the study results," Rep. Stupak said during hearings. He might have added "had they not seen DTC advertising."

YOU MIGHT ALSO LIKE 

These California Nuns Grow Medical Marijuana, But Their City Wants to Shut Them Down

Outraged Republican Senator Vows to Block Appointment of FDA Commissioner Over GMO Salmon

Federal Lawsuit Filed Over North Carolina Anti-Whistleblower Law

Meat Industry Wins in Dietary Guidelines for Americans

Show Comments ()
Sponsored
Popular
Robert Vessels

Fly Fishing in Yellowstone: How One Veteran Found a New Life in the Outdoors

By Lindsey Robinson

Evan Bogart never wanted to sleep in a tent again. Between 2004-2011, he'd served in the U.S. Army as an infantryman and spent three long combat deployments in Afghanistan and Iraq. He'd spent a good portion of his years in service living in a tent in hot and hazardous deserts. He'd had enough of the outdoors; he wanted to be in places with air conditioning, electricity and no reminders of the war-torn lands he had experienced.

Evan separated in 2011 as an E6 Squad Leader, with an honorable discharge and two Purple Hearts. But his own heart was heavy and troubled. He'd become disillusioned with the U.S. military and its goals in the Middle East. The violence and destruction he'd witnessed left him feeling both angry and guilty. He distinctly remembers one moment in Iraq: "An old woman told me I was a bad man, and I realized I agreed with her."

Keep reading... Show less
Popular
Make A Change World

How Two Brothers Convinced the Indonesian Government to Clean Up the World's Most Polluted River

By Gary Bencheghib and Sam Bencheghib

On August 14, we set out to kayak down the world's most polluted river, the Citarum River located in Indonesia, to document and raise awareness about the highly toxic chemicals in its waters and the masses of plastics floating on its surface.

We paddled a total of 68km in two weeks on two plastic bottle kayaks from the village of Majalaya, located just south of Bandung to Pantai Bahagia, the river mouth at the Java Sea. Each kayak was made of 300 plastic bottles to demonstrate that trash can have a second life.

Keep reading... Show less
Popular

General Motors to Run Ohio, Indiana Factories With 100% Wind P​ower

By Greg Alvarez

Last week I predicted it wouldn't be long before we had more news on Fortune 500 wind power purchases. Well, a whole seven days passed before there were new deals to report.

Keep reading... Show less
Popular
South Carolina United Turtle Enthusiasts (S.C.U.T.E) unearthed three baby loggerheads after a nest inventory at Pawleys Island beach. Lorraine Chow

Sea Turtle Population Rebounding But Many Threats Remain

A new study published in Science Advances has found that most global sea turtles populations are recovering after historical declines.

The results from the analysis suggest that conservation programs actually work, and why we must defend the Endangered Species Act (ESA) that protects vulnerable plants and animals, and is currently under attack by political and business interests.

Keep reading... Show less
Sponsored
Popular
www.youtube.com

Baby Rhino Brings New Hope to India’s Manas National Park

A baby rhino spotted alongside its mother in Manas National Park, located in the northeastern Indian state of Assam, is an encouraging new sign that the rhino population in the protected area is on the upswing. The mother, named Jamuna, was rescued as a calf from Kaziranga National Park, located about 200 miles east of Manas and raised at the Center for Wildlife Rehabilitation and Conservation, a facility that cares for injured or orphaned wild animals run by Wildlife Trust of India/International Fund for Animal Welfare and the Assam Forest Department. She was moved to the Manas in 2008 as part of the country's rhino conservation efforts.

The calf is her second since 2013—a positive indication that despite concerns due to poaching of mature males, rhinos in Manas are reproducing.

Keep reading... Show less
Popular
Cedar Mesa Valley of the Gods in the Bears Ears National Monument in southeastern Utah. Bob Wick, BLM

Navajo Nation Readies Legal Action if Trump Shrinks Bears Ears National Monument

Interior Sec. Ryan Zinke's recommendation to reduce the size of the Bears Ears National Monument in Utah could spark a legal battle between the Navajo Nation and the Trump administration.

"We are prepared to challenge immediately whatever official action is taken to modify the monument or restructure any aspect of that, such as the Bears Ears Commission," Ethel Branch, Navajo Nation attorney general, told Reuters.

Keep reading... Show less
Sponsored
Popular
Jilson Tiu / Greenpeace

Nestlé, Unilever, P&G Among Worst Offenders for Plastic Pollution in Philippines Beach Audit

A week-long beach clean up and audit at Freedom Island in Manila Bay has exposed the companies most responsible for plastic pollution in the critical wetland habitat and Ramsar site—one of the worst locations for plastic pollution in the Philippines.

The Greenpeace Philippines and #breakfreefromplastic movement audit, the first of its kind in the country, revealed that Nestlé, Unilever and Indonesian company PT Torabika Mayora are the top three contributors of plastic waste discovered in the area, contributing to the 1.88 million metric tonnes of mismanaged plastic waste in the Philippines per year.

Keep reading... Show less
GMO
www.youtube.com

Arkansas Plant Board Backs Dicamba Ban Next Summer in Blow to Monsanto

The Arkansas Plant Board has approved new regulations that prohibit the use of dicamba from April 16 through Oct. 31, 2018 after receiving nearly 1,000 complaints of pesticide misuse in the state.

Arkansas, which temporarily banned the highly volatile weedkiller in July, could now face legal action from Monsanto, the developers of dicamba-resistant soybeans or cotton and the corresponding pesticide, aka the Xtend crop system.

Keep reading... Show less
Sponsored

mail-copy

Get EcoWatch in your inbox